Breaking News Instant updates and real-time market news.

I

Intelsat

$6.21 /

+0.33 (+5.61%)

14:50
01/28/20
01/28
14:50
01/28/20
14:50

Intelsat drops after Multichannel report on C-Band Senate bill

Shares of Intelsat (I) are dropping after Multichannel reported that a potentially final version of a Senate measure mandating a public auction of C-Band satellite spectrum for 5G has been introduced and includes $5B to relocate incumbent users, including satellite service providers. Intelsat is a satellite operator and member of the C-Band Alliance, which had sought a percentage of the proceeds from the bill rather than a flat fee, per the bill's capped $1B, according to Multichannel. Intelsat shares are down 10.2% to $5.29 after the news. Reference Link

  • 09

    Mar

I Intelsat
$6.21 /

+0.33 (+5.61%)

11/20/19
Fly Intel: Top five analyst upgrades
11/20/19 Raymond James
Intelsat upgraded to Outperform following ~75% pullback at Raymond James
11/20/19 Raymond James
Intelsat upgraded to Outperform from Market Perform at Raymond James
11/18/19 Evercore ISI
Evercore downgrades Intelsat, cuts price target to $11 from $38

TODAY'S FREE FLY STORIES

Conference/Events
Paramount Group management to meet with Morgan Stanley » 16:42
02/16/20
02/16
16:42
02/16/20
16:42
PGRE

Paramount Group

$14.84 /

+0.15 (+1.02%)

Group Dinner Meeting with…

Group Dinner Meeting with President & CEO Behler and CFO Paes will be held in New York on February 25 hosted by Morgan Stanley.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
8x8, Inc. management to meet with Morgan Stanley » 16:38
02/16/20
02/16
16:38
02/16/20
16:38
EGHT

8x8, Inc.

$20.41 /

-0.25 (-1.21%)

Meeting to be held in New…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Bausch Health management to meet with Morgan Stanley » 16:36
02/16/20
02/16
16:36
02/16/20
16:36
BHC

Bausch Health

$27.74 /

+0.305 (+1.11%)

Meeting to be held in New…

Meeting to be held in New York on February 19 hosted by Morgan Stanley.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biotech analyst to hold a KOL luncheon » 16:04
02/16/20
02/16
16:04
02/16/20
16:04

Analysts hold a GU…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call » 16:03
02/16/20
02/16
16:03
02/16/20
16:03

Alternative Energy &…

Alternative Energy & Environmental Services Analyst Windham discusses advanced nuclear energy systems with TerraPower on an Analyst/Industry conference call to be held on February 24 at 11 am.

Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call » 16:01
02/16/20
02/16
16:01
02/16/20
16:01

Washington Research…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Stephens oil and gas analysts to hold an analyst/industry conference call » 15:59
02/16/20
02/16
15:59
02/16/20
15:59

Oil & Gas Analysts,…

Oil & Gas Analysts, along with Brandon Barnes, Senior Analyst for Bloomberg Intelligence, discuss the current state of the energy-related infrastructure in North America, with a specific focus on oil & gas pipeline construction on an Analyst/Industry conference call to be held on February 18 at 11 am.

Conference/Events
Cantor Fitzgerald biotech & specialty pharma analysts to hold a luncheon » 15:57
02/16/20
02/16
15:57
02/16/20
15:57
PFE

Pfizer

$36.49 /

-0.43 (-1.16%)

, LLY

Eli Lilly

$141.13 /

-0.75 (-0.53%)

, DERM

Dermira

$18.75 /

+0.01 (+0.05%)

, REGN

Regeneron

$399.34 /

+0.57 (+0.14%)

, INCY

Incyte

$78.42 /

+0.34 (+0.44%)

, ARNA

Arena Pharmaceuticals

$54.01 /

+0.18 (+0.33%)

Specialty Pharma Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Cellcom Israel announces negotiations to purchase Golan Telecom » 15:27
02/16/20
02/16
15:27
02/16/20
15:27
CEL

Cellcom Israel

$4.04 /

-0.08 (-1.94%)

Cellcom Israel announced…

Cellcom Israel announced that it is in negotiations with Golan Telecom's, or Golan Telecom, shareholders, in regards to possible purchase of its holdings in Golan Telecom. The company added that it cannot guarantee that such discussions will mature into a transaction.

Hot Stocks
Bristol-Myers announced five-year follow-up results from Phase 3 CheckMate -025 » 15:25
02/16/20
02/16
15:25
02/16/20
15:25
BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

Bristol-Myers Squibb…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Bristol-Myers announced updated results from Phase 3 CheckMate -214 study » 15:23
02/16/20
02/16
15:23
02/16/20
15:23
BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

Bristol-Myers Squibb…

Bristol-Myers Squibb announced updated results from the Phase 3 CheckMate -214 study evaluating the combination of Opdivo plus Yervoy versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma. With a minimum follow-up of 42 months, the combination of Opdivo plus Yervoy continues to show superior overall survival, objective response rates, duration of response and complete response rates. The safety profile for Opdivo plus Yervoy was consistent with prior findings and no new safety signals or drug-related deaths occurred with extended follow-up. A significant OS benefit was observed in both patients from the intermediate- and poor-risk and the intent-to-treat populations treated with Opdivo plus Yervoy compared to those treated with sunitinib alone. Of the patients treated with Opdivo plus Yervoy who experienced a complete response, per independent review, that response was ongoing in 84% and 86% of patients in the IP and ITT populations, respectively.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Mirati Therapeutics announces trial initial data in Renal Cell Carcinoma » 08:45
02/16/20
02/16
08:45
02/16/20
08:45
BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

, MRTX

Mirati Therapeutics

$92.14 /

-2.25 (-2.38%)

Mirati Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Opening Day: Revolution Medicines shares soar in trading debut » 08:20
02/16/20
02/16
08:20
02/16/20
08:20
RVMD

Revolution Medicines

$28.00 /

-0.86 (-2.98%)

, GRIL

Muscle Maker

$3.94 /

-0.06 (-1.50%)

, HUIZ

Huize

$10.57 /

+0.06 (+0.57%)

, PASG

Passage Bio

$0.00 /

+ (+0.00%)

Shares of Revolution…

Open Full Text

Conference/Events
Cellectar Biosciences to hold a conference call » 14:35
02/15/20
02/15
14:35
02/15/20
14:35
CLRB

Cellectar Biosciences

$2.90 /

+0.03 (+1.05%)

Key Opinion Leader Dr.…

Key Opinion Leader Dr. Sikander Ailawadhi provides an update of the CLR 131 Phase 1 and Phase 2 Hematology focused trials on a conference call to be held on February 19 at 10:30 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Hard-seltzer consumption growth 'excellent news' for Sam Beer, Barron's says » 11:04
02/15/20
02/15
11:04
02/15/20
11:04
STZ

Constellation Brands

$203.85 /

+2.68 (+1.33%)

, TAP

Molson Coors

$55.23 /

-0.11 (-0.20%)

, BUD

AB InBev

$73.51 /

-0.21 (-0.28%)

, SAM

Boston Beer

$408.59 /

-1.79 (-0.44%)

Hard seltzer has grown…

Hard seltzer has grown from near zero a few years ago to 2.6% the size of beer today, which is excellent news for Boston Beer (SAM), Jack Hough writes in this week's edition of Barron's. Typical of the bunch is Truly Hard Seltzer, which is made by Boston Beer, the author notes, adding that AB InBev (BUD), Molson Coors (TAP), and Constellation Brands (STZ) are among those in or joining the mix. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
ICE's busted bid for eBay 'an opening for investors,' Barron's says » 08:46
02/15/20
02/15
08:46
02/15/20
08:46
EBAY

eBay

$38.17 /

+0.99 (+2.66%)

, ICE

IntercontinentalExchange

$96.83 /

+2.62 (+2.78%)

The news that ICE (ICE)…

The news that ICE (ICE) was interested in buying eBay (EBAY) promptly sent the exchange company's stock sharply lower and eBay's sharply higher, but then everything fell apart as no one understood why a financial exchange would want to own an online marketplace, Steven Sears writes in this week's edition of Barron's. ICE's interest in eBay indicates that the exchange business model may soon evolve anew, the author notes, adding that the eBay play is a sign of a possible future. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Lloyds stock a post-Brexit 'pure U.K. banking play,' Barron's says » 08:42
02/15/20
02/15
08:42
02/15/20
08:42
LYG

Lloyds Banking

$2.93 /

-0.085 (-2.82%)

Investors looking to bet…

Investors looking to bet on a Brexit-fueled jump in Britain's economy should consider buying shares in U.K.-based financial powerhouse Lloyds Banking, Simon Constable writes in this week's edition of Barron's. The stock is cheap and highly geared to the U.K. economy, and investors will also get paid a hefty dividend while they wait, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Bed Bath's hidden assets might be worth about $1B, Barron's says » 08:40
02/15/20
02/15
08:40
02/15/20
08:40
BBBY

Bed Bath & Beyond

$11.18 /

-0.63 (-5.34%)

Pain and patience are in…

Pain and patience are in store for Bed Bath & Beyond shareholders, Carleton English writes in this week's edition of Barron's. With continuing drops in same-store sales expected as the company corrects its pricing and product mix, Wall Street is hoping Bed Bath & Beyond can pull other levers in the short term to boost its stock price-namely, asset sales, the author notes. Investors Barron's spoke with see a roughly $900M opportunity in aggregate if non-core brands such as PersonalizationMall.com, Cost Plus World Market, and others are sold-with hopes that deals will be announced quickly. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Facebook, Google facing real regulatory risk, Barron's says » 08:16
02/15/20
02/15
08:16
02/15/20
08:16
FB

Facebook

$214.21 /

+1.09 (+0.51%)

, AAPL

Apple

$324.91 /

-0.02 (-0.01%)

, GOOGL

Alphabet Class A

$1,518.35 /

+4.81 (+0.32%)

, GOOG

Alphabet

$1,519.63 /

+5.05 (+0.33%)

For months now,…

For months now, regulators, legislators, activists, and presidential candidates have been calling out the toxic impact that big tech platforms are having on privacy, security, and consumer choice, and there are signs that regulation is starting to hurt, Eric Savitz writes in this week's edition of Barron's. But it is actually the self-imposed checks that could be most damaging to tech's bottom line in the months to come, with Google (GOOGL) beginning to limit cookies in its Chrome browser and Apple (AAPL) adding a feature in its iPhone software that alerts consumers when an app tracks their location, the author notes. Meanwhile, Facebook (FB) is starting to feel the effects of restrictions on both ad targeting and measurement, as the company says that "the majority of that impact lies in front of us." Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Natural gas stocks to be avoided except for Cabot, Cheniere, Barron's says » 08:02
02/15/20
02/15
08:02
02/15/20
08:02
LNG

Cheniere Energy

$54.98 /

+0.17 (+0.31%)

, COG

Cabot Oil & Gas

$14.80 /

-0.27 (-1.79%)

Natural gas fell below $2…

Natural gas fell below $2 per million British thermal units on Jan. 21, a level at which most U.S. producers can't make money drilling new wells and absent a ban on hydraulic fracturing or fracking in the U.S., excess supply will probably depress prices for years, Avi Salzman writes in this week's edition of Barron's. That could make most of the industry's stocks poor investments, with exceptions such as Cabot Oil & Gas (COG) and Cheniere Energy (LNG), the author contends. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Week in Review: How Trump's policies moved stocks » 07:34
02/15/20
02/15
07:34
02/15/20
07:34
AMZN

Amazon.com

$2,135.08 /

-14.65 (-0.68%)

, MSFT

Microsoft

$185.38 /

+1.64 (+0.89%)

, TSLA

Tesla

$799.95 /

-4.05 (-0.50%)

, GM

General Motors

$34.76 /

-0.535 (-1.52%)

, WKHS

Workhorse Group

$3.32 /

-0.235 (-6.61%)

, FCAU

Fiat Chrysler

$13.26 /

-0.175 (-1.30%)

, F

Ford

$8.10 /

-0.155 (-1.88%)

, HMC

Honda

$26.80 /

-0.29 (-1.07%)

, NSANY

Nissan

$0.00 /

+ (+0.00%)

, TM

Toyota

$140.10 /

-0.91 (-0.65%)

, DDAIF

Daimler AG

$0.00 /

+ (+0.00%)

, VWAGY

Volkswagen

$0.00 /

+ (+0.00%)

, CSCO

Cisco

$46.97 /

-0.32 (-0.68%)

, NOK

Nokia

$4.33 /

-0.005 (-0.12%)

, ERIC

Ericsson

$9.09 /

+0.015 (+0.17%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14
    Feb
Conference/Events
American Society of Clinical Oncology to hold a symposium » 04:55
02/15/20
02/15
04:55
02/15/20
04:55
ADXS

Advaxis

$1.01 /

-0.025 (-2.42%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$66.38 /

+0.31 (+0.47%)

, CALA

Calithera Biosciences

$6.79 /

+0.1 (+1.49%)

, CRVS

Corvus Pharmaceuticals

$4.33 /

-0.04 (-0.92%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DNDN

Dendreon

$0.00 /

+ (+0.00%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXAS

Exact Sciences

$98.09 /

+3.35 (+3.54%)

, EXEL

Exelixis

$20.77 /

+0.52 (+2.57%)

, HSDEF

Harborside

$0.00 /

+ (+0.00%)

, IMMU

Immunomedics

$18.37 /

-0.38 (-2.03%)

, INCY

Incyte

$78.42 /

+0.34 (+0.44%)

, MRK

Merck

$82.64 /

+0.71 (+0.87%)

, MYGN

Myriad Genetics

$19.41 /

-0.12 (-0.61%)

, NKTR

Nektar

$23.14 /

+0.3 (+1.31%)

, NVS

Novartis

$97.62 /

-0.15 (-0.15%)

, NVTA

Invitae

$27.04 /

+0.795 (+3.03%)

, PFE

Pfizer

$36.49 /

-0.43 (-1.16%)

, PFNX

Pfenex

$13.38 /

+0.29 (+2.22%)

, SGEN

Seattle Genetics

$118.09 /

-0.16 (-0.14%)

, SNY

Sanofi

$49.93 /

-0.06 (-0.12%)

, TROV

Trovagene

$1.69 /

-0.235 (-12.21%)

ASCO-GU Symposium will be…

ASCO-GU Symposium will be held in San Francisco on February 13-15.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Agile Therapeutics announces FDA approval of Twirla transdermal system » 18:47
02/14/20
02/14
18:47
02/14/20
18:47
AGRX

Agile Therapeutics

$4.07 /

-0.055 (-1.33%)

Agile Therapeutics…

Agile Therapeutics announced that the U.S. FDA has approved Twirla transdermal system. Twirla is designed for weekly application to deliver a 30 mcg daily dose of ethinyl estradiol, a type of estrogen, along with a 120 mcg daily dose of levonorgestrel, a well-known progestin with a long history in the category. The newly approved patch can be worn on the abdomen, buttock, or upper torso.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Mattel CEO: The turnaround is working » 18:23
02/14/20
02/14
18:23
02/14/20
18:23
MAT

Mattel

$13.97 /

-0.43 (-2.99%)

In an interview on…

In an interview on CNBC's Mad Money, Mattel CEO Ynon Kreiz said, "2019 was an inflection point in our turnaround. We significantly improved profitability. We grew market share in Q4 and retained global leadership. Our strategy is to turn Mattel into an IP-driven toy company." When asked about the coronavirus, Kreiz said, "So far we are okay, but if it lingers, it will have an impact. We're in a better position than our peers due to our size. We hope to be able to mitigate any challenges in China."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Southwest union seeks mediation for stalled contract negotiations, Reuters says » 18:18
02/14/20
02/14
18:18
02/14/20
18:18
LUV

Southwest

$57.98 /

-0.57 (-0.97%)

The International…

The International Association of Machinists and Aerospace Workers, the union representing Southwest's passenger service and reservation workers, said it is seeking federal mediation to assist with contract talks after two years of negotiations, Reuters' Tracy Rucinski reports. Southwest spent seven years in contract talks with a different union that represents its mechanices prior to reaching a deal last year, and now the IAM, which represents 7,852 Southwest workers, has invoked its right to mediation with the National Mediation Board, Rucinski says. "While many contract issues remain unresolved, the one issue that has completely derailed negotiations is Southwest's treatment of its employees," IAM said. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.